MBX Biosciences, Inc.
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -86.61M | -86.97M | -80.50M | -77.02M | -73.47M |
| Total Depreciation and Amortization | 335.00K | 348.00K | 246.00K | 271.00K | 273.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.51M | 5.10M | 3.18M | 2.27M | 1.78M |
| Change in Net Operating Assets | -719.00K | 1.58M | -620.00K | 3.66M | 4.76M |
| Cash from Operations | -77.48M | -79.95M | -77.69M | -70.81M | -66.65M |
| Capital Expenditure | -2.34M | -1.93M | -1.23M | -886.00K | -631.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -181.69M | -81.78M | -19.85M | -138.04M | -172.17M |
| Cash from Investing | -184.03M | -83.71M | -21.08M | -138.92M | -172.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 278.17M | 190.36M | 189.60M | 176.04M | 174.76M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 63.50M | 63.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.15M | -771.00K | -581.00K | -2.52M | -4.34M |
| Cash from Financing | 277.02M | 189.59M | 189.02M | 237.01M | 233.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 15.52M | 25.94M | 90.26M | 27.28M | -5.52M |